HIMS stock forecast analyzes recent volatility to $15.74, 67% analyst upside to $26.38, strong revenue growth, and technical signals. Is HIMS stock a buy in 2026?
Introduction
Hims & Hers Health (HIMS stock) provides telehealth services for men’s and women’s wellness. It offers personalized treatments for hair loss, sexual health, mental health, and weight management via subscription model.
Investors focus on HIMS stock after sharp March 2026 swings from $14 lows to $16 highs. Healthcare tech faces regulatory scrutiny while consumer telehealth demand grows amid doctor shortages.
Latest Stock Price & Trend
HIMS stock closed at $15.74 on March 6, 2026 (last market close data), down 0.88% from $15.88 prior day on 14.4 million shares volume. Day range $15.21-$15.84 showed tight consolidation.
Five-day trend volatile: March 2 +13.50% spike to $16.48, March 3 -4.00%, March 4 +3.98%, March 5 -3.47% reflecting 10%+ daily swings. One-month downtrend from late February $27+ peaks.
Three-month performance reflects January $32 highs to March $14 lows (-56% drawdown). Six-month uptrend intact from 2025 lows; YTD 2026 down 52% from $32.47 start.
52-week range $13.74 low to $70.43 high captures extreme momentum cycles. Overall direction sideways with basing pattern – investors watch $14 support for accumulation signals.
Technical Analysis
Support holds at $14.31-$15.21 matching March 2 lows where aggressive buying emerged. Support identifies demand zones during corrections.
Resistance targets $16.50-$17.00 recent highs and round number overhead. Breaking $17 confirms short-term momentum resumption.
RSI neutral ~45 after volatile swings, avoiding oversold extremes below 30. RSI measures buying pressure for timing entries/exits.
MACD shows bullish divergence forming after March 2 volume spike. MACD tracks trend acceleration via moving average signals.
50-day average ~$18 resistance above price; 200-day ~$22 confirms correction phase. Volume elevated 14-32M shares validates institutional interest.
Analyst Ratings & Price Targets
13 analysts rate HIMS Hold consensus with $26.38 average target (+67.6% upside from $15.74). Range reflects bullish $35+ to conservative $18 estimates.
No recent major upgrades/downgrades noted. Hold rating balances rapid subscriber growth against regulatory risks for investors.
Insider Activity
No specific recent Form 4 transactions highlighted across sources. Management focused on execution vs. personal trading amid volatility.
202.99M shares float stable; steady activity suggests operational confidence over confidence signals.
Valuation Analysis
Trailing P/E 60.36x reflects high-growth healthcare profile. Forward P/E attractive at current levels versus telehealth peers.
Revenue FY $1.48B with net income $126M demonstrates profitability inflection. Price-to-sales ~7x premium justified by subscriber momentum.
EPS TTM $0.88 positive milestone; market cap $10.65B supports growth multiple. Versus Zoom (mature SaaS) or Teladoc (distressed), HIMS fairly valued for execution trajectory.
Recent Earnings & Catalysts
Earnings date February 23, 2026 drove pre-March volatility. Q4 likely beat subscriber/revenue expectations given price action.
Key catalysts: weight loss GLP-1 offerings, mental health expansion, international telehealth licenses. Subscription model drives recurring revenue stability.
March 2 13.5% volume spike (32.5M shares) suggests positive reaction fading on profit-taking.
Bullish Case
$26 analyst targets (+67%) reflect subscriber growth acceleration. Profitable $126M net income de-risks growth story.
GLP-1 weight loss market explodes; telehealth delivery creates competitive moat vs. traditional clinics.
Bearish Case
Beta 2.61 guarantees 10%+ daily volatility. FDA scrutiny on compounded medications creates regulatory overhang.
P/E 60x vulnerable to growth slowdowns. Competition intensifies from Ro, Lemonaid, traditional pharmacies.
Market Sentiment & Investor Psychology
March 2026 $17.50 puts active showing downside protection demand. $27 calls traded signaling upside bets. Short interest moderate per options flow.
Institutions steady 202M float ownership; retail chases momentum swings. Sentiment neutral: growth vs. valuation balance.
Short-Term Outlook
$15 support critical with volume >20M confirming $17 resistance test. Beta 2.61 expects 8-12% swings.
$14.50-$17 range likely absent earnings catalysts. Healthcare policy news drives sentiment shifts.
Medium to Long-Term Outlook
Subscription telehealth model durable through economic cycles. $1.48B revenue base supports international expansion.
GLP-1 tailwinds and mental health demand create multi-year runway. Long-term investors: accumulate sub-$15, hold core positions.
FAQ
Is HIMS stock a buy right now?
Hold current positions; accumulate sub-$15 offers better margin of safety.
What is the price target for HIMS stock?
$26.38 consensus (+67% upside) from 13 Hold-rated analysts.
What are major risks for HIMS stock?
Regulatory scrutiny, GLP-1 competition, valuation compression, volatility.
HIMS earnings date?
February 23, 2026 – subscriber growth key focus.
HIMS long-term outlook?
Telehealth leadership with GLP-1 weight loss catalyst.
Suggestions
Compare with Opendoor
See our Microsoft stock forecast for healthcare AI synergies.
Read our digital health sector valuation analysis.
Conclusion
Hold existing positions; accumulate sub-$15. HIMS stock trades 60x earnings with $1.48B revenue and $126M profits, but 2.61 beta volatility and regulatory risks demand caution. $26 targets reasonable at execution.
Disclaimer: This article is for informational purposes only and not financial advice.